The night before, he had rolled up with his entourage about 20 minutes late to a packed lecture hall of 500 CrossFitters at the University of Washington campus. He had been invited to speak there by the Freedom Foundation, a local libertarian group. Libertarians love CrossFit. It's neither a wholly owned chain of gyms nor a franchise, but the nucleus of a sprawling worldwide network of entrepreneurs. A local CrossFit gym is referred to as a box, because it can be anywhere and any style, and the culture of any box may be nothing like that of Glassman's company, or of any other CrossFit box. Boxes may even have different business models. And yet, there in the audience was the order spawned from the chaos: rows and rows of passionate CrossFitters, united in their love of the WOD, their muscled physiques rippling beneath T-shirts and hoodies.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”